A detailed history of Lmr Partners LLP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Lmr Partners LLP holds 50,000 shares of VKTX stock, worth $1.63 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
50,000
Previous 50,000 -0.0%
Holding current value
$1.63 Million
Previous $2.65 Million 19.43%
% of portfolio
0.03%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$8.08 - $17.33 $77,026 - $165,206
-9,533 Reduced 29.95%
22,299 $371,000
Q4 2022

Feb 14, 2023

BUY
$2.72 - $9.4 $20,215 - $69,860
7,432 Added 30.46%
31,832 $299,000
Q2 2022

Aug 15, 2022

BUY
$2.11 - $3.15 $51,484 - $76,860
24,400 New
24,400 $71,000
Q4 2018

Feb 14, 2019

SELL
$7.16 - $16.21 $88,182 - $199,642
-12,316 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$9.7 - $19.65 $119,465 - $242,009
12,316 New
12,316 $215,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $2.5B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.